Auro Laboratories Ltd vs Novelix Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Auro Laboratories Ltd is ₹ 239.1 as of 30 Apr 15:30 . The P/E Ratio of Auro Laboratories Ltd is 0 as of March 2021 .The P/E Ratio of Novelix Pharmaceuticals Ltd is 0 as of March 2021 . The Market Cap of Auro Laboratories Ltd is ₹ 0 crore as of March 2021 .The Market Cap of Novelix Pharmaceuticals Ltd is ₹ 5.48 crore as of March 2021 . The revenue of Auro Laboratories Ltd for the Sep '25 is ₹ 9.81 crore as compare to the Jun '25 revenue of ₹ 3.19 crore. This represent the growth of 207.52% The revenue of Novelix Pharmaceuticals Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Auro Laboratories Ltd for the Sep '25 is ₹ 3.33 crore as compare to the Jun '25 ebitda of ₹ 0.45 crore. This represent the growth of 640% The ebitda of Novelix Pharmaceuticals Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Auro Laboratories Ltd changed from ₹ 0.75 crore to ₹ 0.72 crore over 4 quarters. This represents a CAGR of -4.00% The net profit of Novelix Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of 0.0% The Dividend Payout of Auro Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Novelix Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Auro Laboratories Ltd

Auro Laboratories Limited, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API).
Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes.
The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra.
The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards.
Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company's primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments.

About Novelix Pharmaceuticals Ltd

Trimurthi Limited was formerly incorporated on December 13, 1994 with the name Trimurthi Securities Ltd. The name of the Company thereafter got changed from Trimurthi Securities Ltd to Trimurthi Drugs & Pharmaceuticals Ltd. In September 2006, as per the Scheme of Arrangement, the erstwhile Trimurthi Drugs & Pharmaceuticals Ltd amalgamated with the Company.
Also, the name of the Company was changed to Trimurthi Drugs & Pharmaceuticals Ltd and again to Trimurthi Limited in May, 2016. Initially, the company was engaged in finance and investments in securities.
They ceased their operations due to the high volatility in the markets and voluntarily got de-registered as Non-Banking financial company.
Thereafter, the company explored the possibilities of entering into pharmaceutical and drug industry by way of diversification.

FAQs for the comparison of Auro Laboratories Ltd and Novelix Pharmaceuticals Ltd

Which company has a larger market capitalization, Auro Laboratories Ltd or Novelix Pharmaceuticals Ltd?

Market cap of Auro Laboratories Ltd is 149 Cr while Market cap of Novelix Pharmaceuticals Ltd is 58 Cr

What are the key factors driving the stock performance of Auro Laboratories Ltd and Novelix Pharmaceuticals Ltd?

The stock performance of Auro Laboratories Ltd and Novelix Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Auro Laboratories Ltd and Novelix Pharmaceuticals Ltd?

As of May 3, 2026, the Auro Laboratories Ltd stock price is INR ₹239.1. On the other hand, Novelix Pharmaceuticals Ltd stock price is INR ₹40.5.

How do dividend payouts of Auro Laboratories Ltd and Novelix Pharmaceuticals Ltd compare?

To compare the dividend payouts of Auro Laboratories Ltd and Novelix Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.